Clinical Study of Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells
The clinical trial sponsored by CAR-T (Shanghai) Biotechnology Co., Ltd. aims to evaluate the efficacy of dental pulp mesenchymal stem cells in treating severe pneumonia caused by COVID-19. Given the ongoing global health crisis and the urgent need for effective therapies, this trial could position CAR-T as a key player in the regenerative medicine space, particularly in the context of viral pneumonia treatments. The market for COVID-19 therapeutics remains competitive, with numerous players exploring various modalities, including monoclonal antibodies, antivirals, and cell therapies. Successful outcomes could lead to significant commercial opportunities, especially if the therapy demonstrates a favorable safety and efficacy profile compared to existing treatments. Diligence should focus on regulatory pathways, potential partnerships, and the scalability of DPMSC production.
Indication: COVID-19
Modality: protein therapy
Target: Dental pulp mesenchymal stem cells (DPMSCs) as a therapeutic intervention for severe pneumonia induced by novel coronavirus.
Sponsor: CAR-T (Shanghai) Biotechnology Co., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Dental pulp mesenchymal stem cells (DPMSCs) as a therapeutic intervention for severe pneumonia induced by novel coronavirus.
View original source fields
Condition raw: COVID-19
Condition normalized: COVID-19
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Dental pulp mesenchymal stem cells (DPMSCs) as a therapeutic intervention for severe pneumonia induced by novel coronavirus.
Target normalized: Dental pulp mesenchymal stem cells (DPMSCs) as a therapeutic intervention for severe pneumonia induced by novel coronavirus.